Coloplast Agrees to Buy Biotechnology Firm Kerecis for Up to $1.3 Billion
By Dominic Chopping
Danish medical device manufacturer Coloplast said Friday it has agreed to buy wound-care provider Kerecis for up to $1.3 billion.
Kerecis is a biotechnology company that has developed a technology using fish skin to treat wounds, burns and other complex wounds relating to diabetes, veins, trauma, and surgery.
Based in Iceland, it uses skin from fish caught in its local waters and has around 500 employees globally, of which more than two-thirds are in the U.S.
The company will pay $1.2 billion upfront in cash with an earnout potential of up to $100 million and is expected to be financed through an equity capital raise of around 9 billion Danish kroner ($1.32 billion).
The Danish company said the acquisition is expected to accelerate its group organic growth by around one percentage point as of full-year 2024/25 but will be margin dilutive in the short-term.
As a result of the acquisition, Coloplast said it has raised its long-term organic growth guidance to 8%-10%, from 7%-9%, and maintained its long-term earnings before interest and tax margin guidance at more than 30%. However, the EBIT margin in its 2025 strategy is now expected to remain below 30%, having targeted a margin of over 30%.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
July 07, 2023 03:46 ET (07:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now